Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

NASDAQ:ADXS opened at $0.11 on Wednesday. The business has a fifty day simple moving average of $0.05 and a two-hundred day simple moving average of $0.10. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $1.49. The company has a market capitalization of $4.48 million, a P/E ratio of -0.01 and a beta of 1.70.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.